Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 3/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799166 | 0.80 | KCNK3 (0.53) | KCNK3KCNK9LMNAALDH1A1KMT2A | |
| SCHEMBL27021670 | 0.79 | KCNK3 (0.46) | KCNK3KCNK9LMNAALDH1A1KMT2A | |
| SCHEMBL7723710 | 0.77 | CTSL (0.54) | LMNAALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL30827957 | 0.77 | CTSL (0.54) | LMNAALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL10551481 | 0.76 | MEN1 (0.46) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL27744255 | 0.75 | ALDH1A1 (0.39) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL798983 | 0.75 | KMT2A (0.54) | KCNK3KCNK9LMNAALDH1A1KMT2A | |
| SCHEMBL22570394 | 0.74 | GAA (0.55) | KCNK3KCNK9LMNAKMT2AKDM4E | |
| SCHEMBL8195324 | 0.74 | GAA (0.57) | KCNK3KCNK9LMNAKMT2ABCL2 | |
| SCHEMBL30183388 | 0.74 | GAA (0.57) | KCNK3KCNK9LMNAKMT2ABCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | KCNK3 4327/4885KCNK9 4243/4885LMNA 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.